宋林 1刘耀 2王凌 3蒋学华 3谷容 1贾运涛1
作者信息
- 1. 重庆医科大学附属儿童医院药剂科/儿童发育疾病研究教育部重点实验室，重庆 400014
- 2. 第三军医大学西南医院药剂科，重庆 400038
- 3. 四川大学华西药学院临床药学研究中心，成都 610041
- 折叠
摘要
Abstract
OBJECTIVE:To systematically review the efficacy of agomelatine in the treatment of depression in acute phase, and provide evidence-based reference for the clinical treatment. METHODS:Retrieved from Cochrane Library,Medline,EMBase, CJFD,VIP,CBM,Wanfang Database,WHO Clinical Trials Registry Platform and American Clinical Trials Registry Platform, the randomized controlled trials (RCT) about agomelatine versus placebo in the depression patients in acute phase. After quality evaluation and data extraction,Meta-analysis was conducted by using Rev Man 5.2 statistics software. RESULTS:A total of 7 RCT were included,involving 2 378 patients. Results of Meta-analysis showed the effective rate in agomelatine group was obviously bet-ter than placebo group [RR=1.43 ,95%CI(1.29 ,1.59),P<0.001] ,remission rate was obviously better than placebo group [RR=1.27 ,95%CI(1.03 ,1.57),P=0.02] ,and the endpoint score of depression scales was obviously lower than placebo group [MD=-2.92,95%CI(-3.65,-2.20),P<0.001],there was statistically significance. CONCLUSIONS:Agomelatine is effective in the treatment of depression patients in acute phase. However,due to the limit of methodological quality and sample size,it remains to be further verified with more rigorously designed and long-term follow-up of large-scale RCT.关键词
阿戈美拉汀/抑郁症/Meta分析/随机对照试验/系统评价/疗效Key words
Agomelatine/Depression/Meta-analysis/Randomized controlled trial/Systematic review/Efficacy分类
医药卫生
